Level/ Typ | Code | Anzeigename | Codesystem |
---|
0‑L | 100-8 | Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 101-6 | Cefoperazone [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 103-2 | Ceforanide [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 104-0 | Ceforanide [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 105-7 | Ceforanide [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 10653-4 | Clotrimazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 10654-2 | Clotrimazole [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 10697-1 | Nystatin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 10698-9 | Nystatin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 10720-1 | Terbinafine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 10721-9 | Terbinafine [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 107-3 | Cefotaxime [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 108-1 | Cefotaxime [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 10868-8 | Bacitracin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 109-9 | Cefotaxime [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 121-4 | Cefpodoxime [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 111-5 | Cefotetan [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 112-3 | Cefotetan [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 113-1 | Cefotetan [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 115-6 | Cefoxitin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 11575-8 | Cefmetazole [Susceptibility] by Gradient strip | 2.16.840.1.113883.6.1 |
0‑L | 11576-6 | Erythromycin+Sulfisoxazole [Susceptibility] by Gradient strip | 2.16.840.1.113883.6.1 |
0‑L | 11577-4 | Sulfamethoxazole [Susceptibility] by Gradient strip | 2.16.840.1.113883.6.1 |
0‑L | 11578-2 | Sulfisoxazole [Susceptibility] by Gradient strip | 2.16.840.1.113883.6.1 |
0‑L | 116-4 | Cefoxitin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 11-7 | Amikacin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 117-2 | Cefoxitin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 129-7 | Cefsulodin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 119-8 | Cefpodoxime [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 120-6 | Cefpodoxime [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 123-0 | Cefprozil [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 124-8 | Cefprozil [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 12-5 | Amikacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 125-5 | Cefprozil [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 138-8 | Ceftizoxime [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 127-1 | Cefsulodin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 128-9 | Cefsulodin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 132-1 | Ceftazidime [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 13-3 | Amikacin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 133-9 | Ceftazidime [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 134-7 | Ceftazidime [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 136-2 | Ceftizoxime [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 137-0 | Ceftizoxime [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 13968-3 | Penicillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 140-4 | Ceftriaxone [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 141-2 | Ceftriaxone [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 142-0 | Ceftriaxone [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 14332-1 | Para aminosalicylate [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 144-6 | Cefuroxime Parenteral [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 145-3 | Cefuroxime Parenteral [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 152-9 | Cephaloglycin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 146-1 | Cefuroxime Parenteral [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 148-7 | Cephalexin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 149-5 | Cephalexin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 150-3 | Cephalexin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 153-7 | Cephaloglycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 154-5 | Cephaloglycin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 156-0 | Cephaloridine [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 157-8 | Cephaloridine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 15-8 | Amoxicillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 158-6 | Cephaloridine [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 160-2 | Cephalothin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 16099-4 | Ethionamide [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 161-0 | Cephalothin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 16100-0 | Rifabutin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 162-8 | Cephalothin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 16387-3 | Rifabutin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 16421-0 | Azithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 164-4 | Cephapirin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 165-1 | Cephapirin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 16-6 | Amoxicillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 16620-7 | Clarithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 16623-1 | Clofazimine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 166-9 | Cephapirin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 16830-2 | Erythromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 16841-9 | Ethambutol+Rifampin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 168-5 | Cephradine [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 173-5 | Chloramphenicol [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 176-8 | Chlortetracycline [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 169-3 | Cephradine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 170-1 | Cephradine [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 172-7 | Chloramphenicol [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 17-4 | Amoxicillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 174-3 | Chloramphenicol [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 177-6 | Chlortetracycline [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 178-4 | Chlortetracycline [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 182-6 | Cinoxacin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 1-8 | Acyclovir [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 180-0 | Cinoxacin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 181-8 | Cinoxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 18946-4 | Metronidazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18947-2 | Mezlocillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18948-0 | Minocycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18949-8 | Miocamycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18950-6 | Moxalactam [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18951-4 | Nafcillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18952-2 | Nalidixate [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18953-0 | Neomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18954-8 | Netilmicin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18955-5 | Nitrofurantoin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18956-3 | Norfloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18957-1 | Novobiocin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18958-9 | Nystatin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 184-2 | Ciprofloxacin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 198-2 | Cloxacillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 185-9 | Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 186-7 | Ciprofloxacin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 188-3 | Clarithromycin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 18855-7 | 5-Fluorocytosine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18857-3 | Almecillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18859-9 | Amdinocillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18860-7 | Amikacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18861-5 | Amoxicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18862-3 | Amoxicillin+Clavulanate [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18863-1 | Amphotericin B [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18864-9 | Ampicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18865-6 | Ampicillin+Sulbactam [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18866-4 | Azithromycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18867-2 | Azlocillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18868-0 | Aztreonam [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18869-8 | Bacampicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18870-6 | Bacitracin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18871-4 | Butirosin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18872-2 | Capreomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18873-0 | Carbenicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18874-8 | Cefaclor [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18875-5 | Cefadroxil [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18876-3 | Cefamandole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18877-1 | Cefatrizine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18878-9 | Cefazolin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18879-7 | Cefepime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18880-5 | Cefixime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18881-3 | Cefmetazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18882-1 | Cefodizime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18883-9 | Cefonicid [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18884-7 | Cefoperazone [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18885-4 | Ceforanide [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18886-2 | Cefotaxime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18887-0 | Cefotetan [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18888-8 | Cefoxitin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18889-6 | Cefpirome [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18890-4 | Cefpodoxime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18891-2 | Cefprozil [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18892-0 | Cefsulodin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18893-8 | Ceftazidime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18894-6 | Ceftizoxime [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18895-3 | Ceftriaxone [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18896-1 | Cefuroxime Parenteral [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18897-9 | Cephalexin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18898-7 | Cephaloglycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18899-5 | Cephaloridine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18900-1 | Cephalothin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18901-9 | Cephapirin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18902-7 | Cephradine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18903-5 | Chloramphenicol [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18904-3 | Chlortetracycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18905-0 | Cinoxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18906-8 | Ciprofloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18907-6 | Clarithromycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18908-4 | Clindamycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18909-2 | Clotrimazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 189-1 | Clarithromycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 18910-0 | Cloxacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18911-8 | Colistimethate | 2.16.840.1.113883.6.1 |
0‑L | 18912-6 | Colistin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18913-4 | Cyclacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18914-2 | Cycloserine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18915-9 | Demeclocycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18916-7 | Dicloxacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18917-5 | Doxycycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18918-3 | Enoxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18919-1 | Erythromycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18920-9 | Erythromycin+Sulfisoxazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18921-7 | Ethambutol [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18922-5 | Ethionamide [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18923-3 | Floxacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18924-1 | Fluconazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18926-6 | Framycetin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18927-4 | Fusidate [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18928-2 | Gentamicin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18929-0 | Gentamicin.high potency [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18930-8 | Gramicidin D [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18931-6 | Hetacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18932-4 | Imipenem [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18934-0 | Isoniazid [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18935-7 | Kanamycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18936-5 | Kanamycin.high potency [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18937-3 | Ketoconazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18938-1 | Lincomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18939-9 | Lomefloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18940-7 | Loracarbef [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18941-5 | Lymecycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18942-3 | Meclocycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18943-1 | Meropenem [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18944-9 | Methacycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18945-6 | Methicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18959-7 | Ofloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18960-5 | Oleandomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18961-3 | Oxacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18962-1 | Oxytetracycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18963-9 | Pefloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18964-7 | Penicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18965-4 | Penicillin G [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18966-2 | Penicillin V [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18967-0 | Phenethicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18968-8 | Pipemidate [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18969-6 | Piperacillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18970-4 | Piperacillin+Tazobactam [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18971-2 | Pivampicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18972-0 | Polymyxin B [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18973-8 | Pyrazinamide [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18974-6 | Rifampin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18975-3 | Ristocetin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18976-1 | Rolitetracycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18977-9 | Rosoxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18978-7 | Roxithromycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18979-5 | Sisomicin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18980-3 | Spectinomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18981-1 | Spiramycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18982-9 | Streptomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18983-7 | Streptomycin.high potency [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18984-5 | Sulfadiazine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18985-2 | Sulfamethoxazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18986-0 | Sulfisoxazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18987-8 | Sulfonamide [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18988-6 | Talampicillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18989-4 | Teicoplanin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18990-2 | Temafloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18991-0 | Temocillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18992-8 | Terbinafine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18993-6 | Tetracycline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18994-4 | Ticarcillin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18995-1 | Ticarcillin+Clavulanate [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18996-9 | Tobramycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18997-7 | Trimethoprim [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18998-5 | Trimethoprim+Sulfamethoxazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 18999-3 | Troleandomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 19-0 | Amoxicillin+Clavulanate [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 19000-9 | Vancomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 19001-7 | Viomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 190-9 | Clarithromycin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 19149-4 | Rifabutin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 192-5 | Clindamycin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 193-3 | Clindamycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 194-1 | Clindamycin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 20375-2 | Clarithromycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20376-0 | Clofazimine [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20377-8 | Ciprofloxacin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20378-6 | Ceftizoxime [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20379-4 | Doxycycline [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 196-6 | Cloxacillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 197-4 | Cloxacillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 200-6 | Colistimethate by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 201-4 | Colistimethate by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 202-2 | Colistimethate by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 20373-7 | Amikacin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20374-5 | Ampicillin+Sulbactam [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20380-2 | Erythromycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20381-0 | Ethambutol [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20382-8 | Ethionamide [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20383-6 | Isoniazid [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20384-4 | Ofloxacin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20385-1 | Rifampin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20386-9 | Rifabutin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20387-7 | Trimethoprim+Sulfamethoxazole [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20388-5 | Nitrofurazone [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 20389-3 | Mupirocin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 20390-1 | Silver sulfadiazine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 20391-9 | Mafenide [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 20396-8 | Levofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 20397-6 | Sparfloxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 20460-2 | Cefuroxime Oral [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 20461-0 | Pyrazinamide [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 20462-8 | Streptomycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 204-8 | Colistin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 205-5 | Colistin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 20629-2 | Levofloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 206-3 | Colistin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 209-7 | Cyclacillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 20-8 | Amoxicillin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 208-9 | Cyclacillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 210-5 | Cyclacillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 21070-8 | Other Antibiotic [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 212-1 | Cycloserine [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 21316-5 | Grepafloxacin [Susceptibility] by Gradient strip | 2.16.840.1.113883.6.1 |
0‑L | 21367-8 | Levofloxacin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 213-9 | Cycloserine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 214-7 | Cycloserine [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 21-6 | Amoxicillin+Clavulanate [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 216-2 | Demeclocycline [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 217-0 | Demeclocycline [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 23636-4 | Cefdinir [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23637-2 | Cefdinir [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 23638-0 | Grepafloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23639-8 | Grepafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 23640-6 | Quinupristin+Dalfopristin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 218-8 | Demeclocycline [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 220-4 | Dicloxacillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 221-2 | Dicloxacillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 222-0 | Dicloxacillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 225-3 | Doxycycline [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 224-6 | Doxycycline [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 226-1 | Doxycycline [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 228-7 | Enoxacin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 229-5 | Enoxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 230-3 | Enoxacin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 23-2 | Amphotericin B [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 232-9 | Erythromycin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 233-7 | Erythromycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 234-5 | Erythromycin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 236-0 | Erythromycin+Sulfisoxazole [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 23607-5 | Capreomycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23608-3 | Cycloserine [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23609-1 | Kanamycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23610-9 | Sparfloxacin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23611-7 | Para aminosalicylate [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23612-5 | Azithromycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23613-3 | Imipenem [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23614-1 | Trimethoprim [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23615-8 | Vancomycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23616-6 | Viomycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 23627-3 | Clofazimine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23628-1 | Sparfloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23629-9 | Para aminosalicylate [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23641-4 | Quinupristin+Dalfopristin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 23642-2 | Trovafloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23643-0 | Trovafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 23658-8 | Other Antibiotic [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23659-6 | Apramycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23709-9 | Ceftiofur [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23712-3 | Enrofloxacin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 23740-4 | Florfenicol [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 24-0 | Amphotericin B [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 237-8 | Erythromycin+Sulfisoxazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 238-6 | Erythromycin+Sulfisoxazole [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 23925-1 | Penicillin [Susceptibility] by Gradient strip | 2.16.840.1.113883.6.1 |
0‑L | 244-4 | Floxacillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 240-2 | Ethambutol [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 241-0 | Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 242-8 | Ethambutol [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 245-1 | Floxacillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 246-9 | Floxacillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 249-3 | Fluconazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 252-7 | 5-Fluorocytosine [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 248-5 | Fluconazole [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 25452-4 | Itraconazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 25-7 | Amphotericin B [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 257-6 | Framycetin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 250-1 | Fluconazole [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 25174-4 | Amikacin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25175-1 | Amikacin 16 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25176-9 | Amikacin 32 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25177-7 | Amikacin 12 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25178-5 | Amikacin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25179-3 | Amikacin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25180-1 | Ciprofloxacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25181-9 | Ciprofloxacin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25182-7 | Kanamycin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25183-5 | Ethionamide 11 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25184-3 | Rifampin 14 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25185-0 | Streptomycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25186-8 | Pyrazinamide 25 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25187-6 | Ethambutol 7.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25188-4 | Ciprofloxacin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25189-2 | Ciprofloxacin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25190-0 | Clarithromycin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25191-8 | Clarithromycin 16 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25192-6 | Clarithromycin 32 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25194-2 | Ethambutol 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25195-9 | Ethambutol 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25196-7 | Ethionamide 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25198-3 | Ethionamide 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25199-1 | Rifabutin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25200-7 | Rifabutin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25201-5 | Rifabutin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25202-3 | Rifampin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25203-1 | Rifampin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25204-9 | Rifampin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25205-6 | Streptomycin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25206-4 | Streptomycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25207-2 | Cycloserine 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25208-0 | Cycloserine 20 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25209-8 | Cycloserine 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25210-6 | Capreomycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25211-4 | Capreomycin 20 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25212-2 | Capreomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25213-0 | Kanamycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25214-8 | Kanamycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25215-5 | Para aminosalicylate 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25216-3 | Para aminosalicylate 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25217-1 | Isoniazid 0.1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25218-9 | Isoniazid 0.2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25219-7 | Isoniazid 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25220-5 | Cefoxitin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25221-3 | Imipenem 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25222-1 | Cefmetazole 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25223-9 | Doxycycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25224-7 | Erythromycin 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25225-4 | Minocycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25226-2 | Sulfisoxazole 300 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25227-0 | Tobramycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25228-8 | Vancomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25229-6 | Pyrazinamide 100 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25230-4 | Ethambutol 2.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25231-2 | Ethionamide 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25310-4 | Amoxicillin+Clavulanate [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 253-5 | 5-Fluorocytosine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 25366-6 | Cefoxitin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25367-4 | Ceftriaxone [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 25411-0 | Fleroxacin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 254-3 | 5-Fluorocytosine [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 25595-0 | Econazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 25596-8 | Fosfomycin [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 25597-6 | Josamycine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 25607-3 | Miconazole [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 25608-1 | Nitroxoline [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 25637-0 | Econazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 25653-7 | Fosfomycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 256-8 | Foscarnet [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 25702-2 | Josamycine [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 25722-0 | Miconazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 25723-8 | Nitroxoline [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 25800-4 | Tobramycin [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 258-4 | Framycetin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 259-2 | Framycetin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 2-6 | Almecillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 274-1 | Hetacillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 261-8 | Fusidate [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 262-6 | Fusidate [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 263-4 | Fusidate [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 265-9 | Ganciclovir [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 266-7 | Gentamicin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 267-5 | Gentamicin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 268-3 | Gentamicin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 278-2 | Imipenem [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 270-9 | Gramicidin D [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 271-7 | Gramicidin D [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 272-5 | Gramicidin D [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 27-3 | Ampicillin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 276-6 | Hetacillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 275-8 | Hetacillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 279-0 | Imipenem [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 280-8 | Imipenem [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 28-1 | Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 286-5 | Isoniazid [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 287-3 | Isoniazid [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 288-1 | Isoniazid [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 290-7 | Kanamycin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 291-5 | Kanamycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 292-3 | Kanamycin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 29254-0 | Linezolid [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 29255-7 | Linezolid [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 29258-1 | Linezolid [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 29315-9 | Isoniazid 0.4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | 2.16.840.1.113883.6.1 |
0‑L | 294-9 | Ketoconazole [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 296-4 | Ketoconazole [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 298-0 | Lincomycin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 295-6 | Ketoconazole [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 29-9 | Ampicillin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 299-8 | Lincomycin [Susceptibility] by Minimum inhibitory concentration (MIC) | 2.16.840.1.113883.6.1 |
0‑L | 300-4 | Lincomycin [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 302-0 | Lomefloxacin [Susceptibility] by Minimum lethal concentration (MLC) | 2.16.840.1.113883.6.1 |
0‑L | 308-7 | Loracarbef [Susceptibility] by Disk diffusion (KB) | 2.16.840.1.113883.6.1 |
0‑L | 30268-7 | Zidovudine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30269-5 | Lamivudine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30270-3 | Didanosine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30271-1 | Zalcitabine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30272-9 | Stavudine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30273-7 | Abacavir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30274-5 | Adefovir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30275-2 | Nevirapine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30276-0 | Delavirdine [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30277-8 | Efavirenz [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30278-6 | Indinavir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30279-4 | Ritonavir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30280-2 | Nelfinavir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30281-0 | Saquinavir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30282-8 | Zidovudine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30283-6 | Lamivudine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30284-4 | Didanosine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30285-1 | Zalcitabine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30286-9 | Stavudine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30287-7 | Abacavir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30288-5 | Adefovir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30289-3 | Nevirapine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30290-1 | Delavirdine [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30291-9 | Efavirenz [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30292-7 | Indinavir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30293-5 | Ritonavir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30294-3 | Nelfinavir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30295-0 | Saquinavir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30296-8 | Amprenavir [Susceptibility] by Phenotype method | 2.16.840.1.113883.6.1 |
0‑L | 30297-6 | Amprenavir [Susceptibility] by Genotype method | 2.16.840.1.113883.6.1 |
0‑L | 30298-4 | Lamivudine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 30299-2 | Amprenavir [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 30300-8 | Didanosine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 30301-6 | Zalcitabine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 30302-4 | Stavudine [Susceptibility] | 2.16.840.1.113883.6.1 |
0‑L | 30303-2 | Abacavir [Susceptibility] | 2.16.840.1.113883.6.1 |
Dieses Value Set beinhaltet 1471 Codes. Um die Publikationsgröße überschaubar zu halten, wird nur eine Auswahl (500 Codes) des ganzen Sets von Codes gezeigt. |
|